The endocannabinoid system in targeting inflammatory neurodegenerative diseases

Trends in Pharmacological Sciences

Volumn 28, Issue 4, 2007, Pages 180-187

  Centonze, Diego ^a,b   Finazzi Agrò, Alessandro ^a   Bernardi, Giorgio ^a,b   Maccarrone, Mauro ^b,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABIS; CAPSAICIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE INHIBITOR; LIPOPROTEIN LIPASE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; O 3841; OL 135; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL ACTIVITY; CANNABIS SMOKING; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DISEASE EXACERBATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENCEPHALITIS; HIV ASSOCIATED DEMENTIA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; NERVE DEGENERATION; RECEPTORS, CANNABINOID;

EID: 33947591537     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.02.004     Document Type: Review

References (65)

1. Zipp F., and Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 29 (2006) 518-527
2. Aktas O., et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46 (2005) 421-432
3. Block M.L., and Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76 (2005) 77-98
4. Allan S.M., et al. Interleukin-1 and neuronal injury. Nat. Rev. Immunol. 5 (2005) 629-640
5. Linker R.A., et al. EAE and β-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. Neurobiol. Dis. 19 (2005) 218-228
6. Babcock A.A., et al. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J. Neurosci. 23 (2003) 7922-7930
7. Chaudhuri A. Interferon β, progressive MS, and brain atrophy. Lancet Neurol. 4 (2005) 208-209
8. Maragakis N.J., and Rothstein J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2 (2006) 679-689
9. Bonifati D.M., and Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. 44 (2007) 999-1010
10. McGeer P.L., et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
11. Marchetti B., and Abbracchio M.P. To be or not to be (inflamed) - is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol. Sci. 26 (2005) 517-525
12. Zandi P.P., et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59 (2002) 880-886
13. Gao H.M., et al. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24 (2003) 395-401
14. Bonuccelli U., and Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology 67 Suppl. 2 (2006) S30-S38
15. Armentero M.T., et al. Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiol. Dis. 24 (2006) 492-505
16. Alexianu M.E., et al. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57 (2001) 1282-1289
17. Henkel J.S., et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 55 (2004) 221-235
18. Tikka T.M., et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 125 (2002) 722-731
19. Pompl P.N., et al. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 17 (2003) 725-727
20. Gordon P.H., et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 66 (2006) 1117-1119
21. Schwartz M., and Kipnis J. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J. Neurol. Sci. 233 (2005) 163-166
22. Filippi M., and Rocca M.A. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J. Neurol. 252 (2005) S16-S24
23. Hauser S.L., and Oksenberg J.R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52 (2006) 61-76
24. Waxman S.G. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat. Rev. Neurosci. 7 (2006) 932-941
25. Ozdener H. Molecular mechanisms of HIV-1 associated neurodegeneration. J. Biosci. 30 (2005) 391-405
26. Fowler C.J. Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 685-696
27. Di Marzo V., et al. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3 (2004) 771-784
28. Ortega-Gutiérrez S. Therapeutic perspectives of inhibitors of endocannabinoid degradation. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 697-708
29. Maccarrone M. Fatty acid amide hydrolase: a potential target for next generation therapeutics. Curr. Pharm. Des. 12 (2006) 759-772
30. Marsicano G., et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
31. Sarne Y., and Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 677-684
32. Van der Stelt M., and Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromol. Med 7 (2005) 37-50
33. Di Marzo V., et al. Anandamide: some like it hot. Trends Pharmacol. Sci. 22 (2001) 346-349
34. Ramirez B.G., et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005) 1904-1913
35. Van der Stelt M., et al. Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 63 (2006) 1410-1424
36. Lastres-Becker I., et al. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005) 96-107
37. Kim S.R., et al. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J. Neurosci. 25 (2005) 662-671
38. McKinney M.K., and Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74 (2005) 411-432
39. Raman C., et al. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5 (2004) 33-39
40. Bilsland L.G., et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 20 (2006) 1003-1005
41. Huntley A. A review of the evidence for efficacy of complementary and alternative medicines in MS. Int. MS J. 13 (2006) 5-12
42. Arevalo-Martin A., et al. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23 (2003) 2511-2516
43. Eljaschewitsch E., et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49 (2006) 67-79
44. Consroe P., et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38 (1997) 44-48
45. Mestre L., et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 92 (2005) 1327-1339
46. Ortega-Gutierrez S., et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J. 19 (2005) 1338-1340
47. Pryce G., et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126 (2003) 2191-2202
48. Ehrhart J., et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2 (2005) 29-32
49. Bari M., et al. New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev. Med. Chem. 6 (2006) 109-120
50. Hogestatt E.D., et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J. Biol. Chem. 280 (2005) 31405-31412
51. Karanian D.A., et al. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J. Neurosci. 25 (2005) 7813-7820
52. Witting A., et al. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6362-6367
53. Bisogno T., et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim. Biophys. Acta 176 (2006) 205-212
54. Pertwee R.G. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol. 168 (2005) 1-51
55. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5 (2005) 400-411
56. Kishimoto S., et al. 2-Arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J. Biol. Chem. 278 (2003) 24469-24475
57. Melis M., et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J. Neurosci. 24 (2004) 10707-10715
58. Oka S., et al. Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. J. Biol. Chem. 280 (2005) 18488-18497
59. Okamoto Y., et al. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279 (2004) 5298-5305
60. Kathuria S., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9 (2003) 76-80
61. Tarzia G., et al. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. ChemMedChem 1 (2006) 130-139
62. Singh Tahim A., et al. Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience 136 (2005) 539-548
63. Tsuboi K., et al. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J. Biol. Chem. 280 (2005) 11082-11092
64. Liu J., et al. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13345-13350
65. Wei B.Q., et al. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 281 (2006) 36569-36578